Review of the Evidence for Pulmonary Rehabilitation in COPD: Clinical Benefits and Cost-Effectiveness
Respiratory Care · 2024-06 · 69 (6) · 686-696
DOI: 10.4187/respcare.11541 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Respiratory Care, online erschienen am 28.05.2024. Verfasst von Courtney E Lamberton und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, North Carolina. courtney.lamberton@duke.edu. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Cost-Benefit Analysis, Quality of Life, Exercise Therapy. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: COPD
Abstract (Originalsprache)
COPD is a common and lethal chronic condition, recognized as a leading cause of death worldwide. COPD is associated with significant morbidity and disability, particularly among older adults. The disease course is marked by periods of stability and disease exacerbations defined by worsening respiratory status resulting in a high burden of health care utilization and an increased risk of mortality. Treatment is focused on pharmacologic therapies, but these are not completely effective. Pulmonary rehabilitation (PR) represents a key medical intervention for patients with chronic respiratory diseases, including COPD. PR provides individualized and progressive exercise training, education, and self-management strategies through a comprehensive and multidisciplinary program. PR has been associated with improvement in exercise capacity, health-related quality of life, and dyspnea in patients living with COPD. Moreover, PR has been associated with improvements in hospital readmission and 1-y survival. In addition to the clinical benefits, PR is estimated to be a cost-effective medical intervention. Despite these benefits, participation in PR remains low. We will review the evidence for PR in each of these benefit domains among patients with stable COPD and in those recovering from a COPD exacerbation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, North Carolina. courtney.lamberton@duke.edu.
- Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, North Carolina; and Duke Clinical Research Institute, Durham, North Carolina.
Förderung
- NIA NIH HHS
Zitieren
APA
Lamberton, C. E., & Mosher, C. L. (2024). Review of the Evidence for Pulmonary Rehabilitation in COPD: Clinical Benefits and Cost-Effectiveness. Respiratory Care, 69(6), 686-696. https://doi.org/10.4187/respcare.11541
Vancouver
Lamberton CE, Mosher CL. Review of the Evidence for Pulmonary Rehabilitation in COPD: Clinical Benefits and Cost-Effectiveness. Respiratory Care. 2024;69(6):686-696. doi:10.4187/respcare.11541
BibTeX
@article{Lamberton2024,
author = {Lamberton, Courtney E and Mosher, Christopher L},
title = {Review of the Evidence for Pulmonary Rehabilitation in COPD: Clinical Benefits and Cost-Effectiveness},
journal = {Respiratory Care},
year = {2024},
volume = {69},
number = {6},
pages = {686--696},
doi = {10.4187/respcare.11541}
}
EUVIMED